Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRC | P08575 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 5/20 | 0.54 |
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | CES2 | O00748 | 1/20 | 0.49 |
| ▸ | CES1 | P23141 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.48 |
| ▸ | RELA | Q04206 | 1/20 | 0.48 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.47 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.47 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31303067 | 1.00 | PTPRC (0.57) | PTPRCTSHRMAPTKMT2AALDH1A1 | |
| SCHEMBL4438465 | 0.94 | PTPRC (0.52) | PTPRCTSHRMAPTKMT2AALDH1A1 | |
| SCHEMBL6622555 | 0.85 | PTPRC (0.59) | PTPRCTSHRMAPTKMT2AALDH1A1 | |
| SCHEMBL1644964 | 0.85 | PTPRC (0.59) | PTPRCTSHRMAPTKMT2AALDH1A1 | |
| SCHEMBL1645746 | 0.85 | PTPRC (0.59) | PTPRCTSHRMAPTKMT2AALDH1A1 | |
| SCHEMBL4656742 | 0.82 | PTPRC (0.52) | PTPRCTSHRMAPTKMT2AALDH1A1 | |
| SCHEMBL7664781 | 0.81 | PTPRC (0.55) | PTPRCTSHRMAPTKMT2AALDH1A1 | |
| SCHEMBL15271675 | 0.81 | TSHR (0.54) | PTPRCTSHRMAPTKMT2AALDH1A1 | |
| SCHEMBL1645915 | 0.80 | PTPRC (0.54) | PTPRCTSHRMAPTKMT2AALDH1A1 | |
| SCHEMBL6680006 | 0.80 | PTPRC (0.54) | PTPRCTSHRMAPTKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024258789-A1 | MODULATORS OF CDK2 AND USES THEREOF | TRIANA BIOMEDICINES, INC. (US) | 2024-12-19 | — | — | WO | disclosed |
| CN-108383836-B | Heterocyclic compounds as MEK inhibitors | 鲁宾有限公司 | 2021-11-12 | — | — | CN | disclosed |
| EP-2834237-B1 | HETEROCYCLYL COMPOUNDS AS MEK INHIBITORS | LUPIN LTD (IN) | 2018-06-06 | — | — | EP | disclosed |
| US-9969731-B2 | Heterocyclyl compounds as MEK inhibitors | LUPIN LIMITED (IN) | 2018-05-15 | — | — | US | disclosed |
| US-9969731-B2 | Heterocyclyl compounds as MEK inhibitors | LUPIN LIMITED (IN) | 2018-05-15 | — | — | US | disclosed |
| US-9969731-B2 | Heterocyclyl compounds as MEK inhibitors | LUPIN LIMITED (IN) | 2018-05-15 | — | — | US | disclosed |
| US-20170101408-A1 | HETEROCYCLYL COMPOUNDS AS MEK INHIBITORS | LUPIN LIMITED (IN) | 2017-04-13 | — | — | US | disclosed |
| US-20170101408-A1 | HETEROCYCLYL COMPOUNDS AS MEK INHIBITORS | LUPIN LIMITED (IN) | 2017-04-13 | — | — | US | disclosed |
| US-20170101408-A1 | HETEROCYCLYL COMPOUNDS AS MEK INHIBITORS | LUPIN LIMITED (IN) | 2017-04-13 | — | — | US | disclosed |
| US-9555035-B2 | Heterocyclyl compounds as MEK inhibitors | LUPIN LIMITED (IN) | 2017-01-31 | — | — | US | disclosed |
| WO-2013136249-A1 | HETEROCYCLYL COMPOUNDS AS MEK INHIBITORS | LUPIN LIMITED (IN) | 2013-09-19 | — | — | WO | disclosed |
| WO-2013135126-A1 | RICE TRANSPLANTER-MOUNTED LIQUID REAGENT APPLICATION DEVICE, AND METHOD OF APPLYING LIQUID REAGENT DURING RICE PLANTING USING SAME | YAMATO NOHJI CO., LTD. (JP) | 2013-09-19 | — | — | WO | disclosed |
| WO-2013136249-A1 | HETEROCYCLYL COMPOUNDS AS MEK INHIBITORS | LUPIN LIMITED (IN) | 2013-09-19 | — | — | WO | disclosed |
| US-20110183969-A1 | ANTIFUNGAL COMBINATION THERAPY | F2G LTD (GB) | 2011-07-28 | — | — | US | disclosed |
| EP-2303329-A1 | ANTIFUNGAL COMBINATION THERAPY | F2G Limited (GB) | 2011-04-06 | — | — | EP | disclosed |
| CN-101679410-A | 2-[(2-substituted)-ind0lizin-3-yl]-2-oxo-acetamide derivatives as antifungal agents | F2G LTD | 2010-03-24 | — | — | CN | disclosed |
| US-20100056511-A1 | 2- [ (2-SUBSTITUTED) -IND0LIZIN-3-YL] -2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS | F2G LTD. | 2010-03-04 | — | — | US | disclosed |
| WO-2009144473-A1 | ANTIFUNGAL COMBINATION THERAPY | F2G LIMITED (GB) | 2009-12-03 | — | — | WO | disclosed |
| EP-2097413-A1 | 2-[(2-SUBSTITUTED)-IND0LIZIN-3-YL]-2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS | F2G Limited (GB) | 2009-09-09 | — | — | EP | disclosed |
| WO-2008062182-A1 | 2- [ (2-SUBSTITUTED) -IND0LIZIN-3-YL] -2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS | F2G LTD (GB) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183969-A1 | ANTIFUNGAL COMBINATION THERAPY | IDO1, FOXM1, IPO5 | PTPRC 3824/4885TSHR 1951/4885MAPT 1771/4885 |
| US-20100056511-A1 | 2- [ (2-SUBSTITUTED) -IND0LIZIN-3-YL] -2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS | NAT1, AGXT, CYP1A2 | PTPRC 4362/4885TSHR 2634/4885MAPT 2950/4885 |
| US-20170101408-A1 | HETEROCYCLYL COMPOUNDS AS MEK INHIBITORS | NRAS, BRAF, KRAS | PTPRC 1067/4885TSHR 3106/4885MAPT 3995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.